Loading
Life sciences · Journal article
Gynecologic Cancer · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Despite advances with surgery, platinum-based chemotherapy, anti-angiogenics, and poly(ADP-ribose) polymerase (PARP) inhibition, the treatment of ovarian cancer remains challenging due to late presentation, molecular heterogeneity, rapid emergence of resistance, and a complex and dynamic tumor microenvironment (TME). In this perspective, we will discuss major challenges in ovarian cancer therapy, focusing on how the ovarian cancer TME, including both solid tumor lesions and malignant ascites, impacts therapeutic efficacy. We also discuss emerging therapies, both at the pre-clinical stage and in clinical trials.